Navigation Links
ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants

it is possible that ANA380/LB80380 used in combination with these existing drugs may help prevent the emergence of resistance. These new results are also consistent with previously reported clinical data showing that ANA380 is active in patients refractory to lamivudine."

"Clearly, we are encouraged by these study results and believe they support additional clinical evaluation to confirm the potential broad clinical utility of ANA380 in treating patients with chronic HBV infection," said In-Chull Kim, Ph.D., President and Chief Executive Officer of LG Life Sciences.

Anadys and LG Life Sciences entered into a Joint Development and License Agreement in April 2004 providing for the global development of ANA380 and pursuant to which Anadys acquired commercialization rights to ANA380 in North America, Europe, Japan and the rest of the world other than China, Korea, India and countries in Southeast Asia. Next steps for the program, including a proposed Phase IIb dose selection clinical trial, are under discussion between Anadys and LGLS.

Study Methods

HBV mutant strains were generated from a wild-type strain of HBV genotype D through site-directed mutagenesis. Mutant strains encoded polymerases resistant to lamivudine, adefovir, entecavir or telbivudine. Replicate HepG2 cell cultures were infected with HBV DNA using baculovirus vectors and were exposed to different concentrations of each drug for seven days. Viral DNA then was extracted and quantified. EC50 values, which were calculated from averages of three independent experiments, were used to evaluate susceptibility.

Clinical Background

ANA380 is an oral prodrug of ANA317 (LB80317), a nucleotide analog. Data from 62 HBV infected patients from a previous Phase II study showed that patients treated daily with ANA380 at 90 mg, 150 mg and 240 mg dose levels experienced reduction in plasma HBV viral DNA at 12 weeks of 3.9 log10, 3.9 log10 and 4.1 log10 units, respectively, (greate
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
3. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
6. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
7. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
(Date:7/28/2014)... July 28, 2014 STAAR Surgical Company (NASDAQ: ... marketer of implantable lenses and delivery systems for the ... results and conference call with investors to July 31, ... The Company rescheduled the release date and conference call ... for Hideo Watanabe , President of STAAR Japan, ...
(Date:7/28/2014)... SOUTH SAN FRANCISCO, Calif. , July 28, 2014 ... ) today provided an update on the status of ... KB001-A collaboration with Sanofi Pasteur.  ... has reached an agreement with Sanofi Pasteur to regain ... the collaboration and licensing agreement entered into in 2010 ...
(Date:7/28/2014)... July 28, 2014  Serco Inc., a provider ... Company has been awarded a re-compete contract to ... and its Deployable Medical Systems.  Serco will provide ... to provide world-class healthcare to meet warfighter and ... the globe. The five year contract has a ...
Breaking Medicine Technology:STAAR Surgical Moves Second Quarter Earnings Release and Conference Call One Day to July 31 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 3KaloBios Provides Update on KB001-A Partnership and Clinical Status 4KaloBios Provides Update on KB001-A Partnership and Clinical Status 5KaloBios Provides Update on KB001-A Partnership and Clinical Status 6Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
... and Non-Whites New to Antiretroviral Therapy Respond ... Similarly to ... treatment,regimens containing once-daily or twice-daily dosing of Abbott,s (NYSE:,ABT) protease ... (reducing the amount of HIV-1),and improving the immune system (increasing ...
... Tolerx, Inc., a,biopharmaceutical company engaged in the ... of immune-mediated diseases, announced today,that Genentech, a collaborator, ... anti-CD4 monoclonal antibody, into a phase 1 clinical ... is evaluating the,safety and tolerability of both single ...
Cached Medicine Technology:Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 3Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 4Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 5Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 6Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 7Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 8Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3
(Date:7/28/2014)... controlling red blood cell development have spread from Africa ... to a new study led by King,s College London. ... to look for the origin of changes in a ... adulthood. Fetal haemoglobin is normally found in fetuses and ... are able to keep making it as adults experience ...
(Date:7/28/2014)... NAPW honors Pamela ... Center, as a 2014 Professional Woman of the Year. ... leadership in community health. As the largest, most-recognized networking ... industry and profession, the National Association of Professional Women ... 600,000 members and nearly 300 Local Chapters. , In ...
(Date:7/28/2014)... 2014 Evolve Medical Clinics opened its first ... members virtual visits and dramatic operational changes that are set ... state that as many as 70% of all primary and ... to leave your office or home for a throat infection, ... cholesterol,” CEO and Founder Michael R. Freedman, MD said. “Doctor’s ...
(Date:7/28/2014)... The “Tissue Diagnostics Market by ... & Workflow, Special Staining), Disease (Breast Cancer, ... Cell Lung Cancer and Others), Product (Instruments ... Laboratories, Contract Research Organizations and Others) & ... & RoW) - Trends & Forecast to ...
(Date:7/28/2014)... Dallas, Texas (PRWEB) July 29, 2014 ... provides key market data on the China Surgical ... of US dollars, volume (in units) and average ... RF Generators, Electrocautery Generators, Ultrasonic Generators and Argon ... company shares and distribution shares data for each ...
Breaking Medicine News(10 mins):Health News:Study tracks worldwide spread of beneficial blood cell gene variant 2Health News:Study tracks worldwide spread of beneficial blood cell gene variant 3Health News:National Association of Professional Women Announces Pamela A. Schulters, Head Nurse at Kings County Hospital Center, a 2014 Professional Woman of the Year 2Health News:Evolve Medical Clinics to Open First Next Generation Primary and Urgent Care Facility 2Health News:Evolve Medical Clinics to Open First Next Generation Primary and Urgent Care Facility 3Health News:Evolve Medical Clinics to Open First Next Generation Primary and Urgent Care Facility 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 2Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 3Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 4
... rhinosinusitis – an often recurring combination of congestion, discolored ... quality of life. ,A group of 25 physicians ... the first clinical trial guidelines for researchers working to ... ,The U.S. Food and Drug Administration (FDA) has issued ...
... be overcome by a newly developed vaccine according to ... funds from the government, said that their vaccine worked ... mice. This bacteria causes a range of potentially fatal ... ,Most hospital-acquired infections are commonly caused by it, causing ...
... convey the poisonous toxic meth chemicals to their unborn fetus ... Study. , ,Motherisk lab at the Hospital for Sick ... of adults and young children to gauge their exposure to ... from the expectant mother to the unborn child. ...
... Stern Review as a timely and authoritative reminder of ... world’s human population if the international community failed to ... prepared by former World Bank chief economist, Sir Nicholas ... Minister, Tony Blair, as the most important he has ...
... commonly prescribed invasive test performed during pregnancies in the ... them based on guidelines from the American College of ... studies and recommendations by the CDC that were based ... have suggested that amniocentesis increases the rate of miscarriage ...
... a recent research, an infant’s risk of cot death or ... defects that affect breathing and temperature control. // ... SIDS. The findings were published in the Journal of the ... these infants had flaws in their brainstem that affected the ...
Cached Medicine News:Health News:New Rhinosinusitis Clinical Trials Guidance Developed 2Health News:Vaccine may overcome Common Infections: Researchers 2Health News:A Timely Reminder Of Devastating Health Impact Of Climate Change 2Health News:Amniocentesis Safer for Pregnant Women 2Health News:Brain stem Defects associated with SIDS 2
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTC/1Q chairs are recommended for ... clean room, static control, health care ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With cast ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With cast ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
Medicine Products: